Finding More in Less: Precision Medicine for Pancreatic Cancer Using Residual Cytology Samples
In a real clinical setting, we show that residual LBC samples from PDAC are valid for molecular analysis, preserving the quality of nucleic acids. Residual LBC may be the only available sample and should be preserved to ensure patient access to targeted therapies.
Authors
- Clara Alfaro‐Cervelló (ORCID: https://orcid.org/0000-0002-3737-4028)
- Luis Sánchez Sabater
- Maria Andrea Ortega (ORCID: https://orcid.org/0000-0002-0447-9982)
- Elena Muñoz‐Forner (ORCID: https://orcid.org/0000-0002-6336-0076)
- Desamparados Compañ
- Vicente Sánchiz
- Constanza Galleguillos Galindo
- Antonio Ferrández (ORCID: https://orcid.org/0000-0003-3406-3838)
- V. Gambardella
- D. Roda
- Andrés Peña
- I. Mora Oliver
- Rosana Villagrasa
- Andres Cervantes
- Raquel Antón‐Peñalver
- Jose Francisco González‐Muñoz
- Marisol Huerta
- Clara Arnau
Institutions
- Universitat de València (ES)
- Hospital Clínico Universitario de Valencia (ES)
- Hospital General Universitario De Valencia (ES)
- INCLIVA Health Research Institute (ES)
Publication Details
- Journal
- Cytopathology
- Published
- 2026-01-26
- DOI
- https://doi.org/10.1111/cyt.70055
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00